Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist

British Journal of Pharmacology

Volumn 117, Issue 7, 1996, Pages 1558-1564

  Akiyama, Toshiharu ^a   Tachibana, Issei ^a   Hirohata, Yoshihide ^a   Shirohara, Hisashi ^a   Yamamoto, Mitsuyoshi ^a   Otsuki, Makoto ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

CCKA receptor antagonist; Isolated pancreatic acini; Residual inhibition; TP 680; Unsurmountable inhibition

Indexed keywords

1 (3 (3 CARBOXYPYRIDINE 2 YL) THIO 2 (INDOL 2 YL) CARBONYLAMINO)PROPIONYL 4 DIPHENYLMETHYL PIPERAZINE; AMYLASE; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ OCTAPEPTIDE; DEVAZEPIDE; LOXIGLUMIDE; SERINE DERIVATIVE; TP 680; UNCLASSIFIED DRUG;

ACINAR CELL; AMYLASE RELEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; MALE; NONHUMAN; PANCREAS; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

AMYLASES; ANIMALS; BENZODIAZEPINONES; BINDING, COMPETITIVE; CEREBRAL CORTEX; CYSTEINE; DEVAZEPIDE; INTRACELLULAR MEMBRANES; MALE; NIACIN; PANCREAS; PROGLUMIDE; RATS; RATS, WISTAR; RECEPTOR, CHOLECYSTOKININ A; RECEPTORS, CHOLECYSTOKININ; SINCALIDE;

EID: 0029969493     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15321.x     Document Type: Article

References (32)

1. AKIYAMA, T. & OTSUKI, M. (1994). Characterization of a new cholecystokinin receptor antagonist FK480 in in vitro isolated rat pancreatic acini. Pancreas, 9, 324-331.
2. BEGLINGER, C. (1991). Efficient treatment of biliary colics with loxiglumide. In Cholecystokinin in Antagonists in Gastroenterology. ed. Adler, G. & Beglinger, C. pp. 209-210. Berlin-Heidelberg: Springer-Verlag.
3. BEGLINGER, C., HILDEBRANDO, O., ADLER, G., WERTH, B., LUO, H., DELCO, F. & GYR, J. (1992a). Postprandial control of gallbladder contraction and exocrine pancreatic secretion in man. Eur. J. Clin. Invest., 22, 827-834.
4. BEGLINGER, C., HILDEBRAND, P., MEIER, R., BAUERFEIND, P., HASSLOCHER, H., URSCHELER, N., DELCO, F., EBERLE, A. & GYR, K. (1992b). A physiological role for cholecystokinin as a regulator of gastric secretion. Gastroenterology, 103, 490-495.
5. CANTOR, P., MORTENSEN, P.E., MYHRE, J., GJORUP, I., WORNING, H., STAHL, E. & SURVILL, T.T. (1992). The effect of the cholecystokinin receptor antagonist MK-329 on meal-stimulated pancreaticobiliary output in humans. Gastroenterology, 102, 1742-1751.
6. CESKA, M., BIRATH, K. & BROWN, B. (1969). A new and rapid method for the clinical determination of α-amylase activities in human serum and urine. Clin. Chim. Acta, 26, 437-444.
7. CHANG, R.S.L. & LOTTI, V.J. (1986). Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc. Natl. Acad. Sci. U.S.A., 83, 4923-4926.
8. FRIED, M., SCHWIZER, W., BEGLINGER, C., KELLER, U., JANSEN, J.B. & LAMERS, C.B. (1991). Physiological role of cholecystokinin on postprandial insulin secretion and gastric meal emptying in man: Studies with the cholecystokinin receptor antagonist loxiglumide. Diabetologia, 34, 721-726.
9. GADDUM, J.H., HAMEED, K.A., HATHWAY, D.E. & STEPHENS, F.F. (1955). Quantitative studies of antagonists for 5-hydroxytryptamine. Q.J. Exp. Physiol., 40, 49-74.
10. HERRINGTON, M.K. & ADRIAN, T.E. (1995). On the role of cholecystokinin in pancreatic cancer. Int. J. Pancreatol., 17, 121-138.
11. HILDEBRAND, P., BEGLINGER, C., GYR, K., JANSEN, J.B.M.J., ROVATI, L.C., ZUERCHER, M., LAMERS, C.B.H.W., SETNIKAR, I. & STALDER, G.A. (1990). Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man. J. Clin. Invest., 85, 640-646.
12. HUGHES, J., BODEN, P., COSTALL, B., DOMENEY, A., KELLY, E., HORWELL, D.C., HUNTER, J.C., PINNOCK, R.D. & WOODRUFF, G.N. (1990). Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc. Natl. Acad. Sci. U.S.A., 87, 6728-6732.
13. LIDDLE, R.A., GERTZ, B.J., KANAYAMA, S., BECCARIA, L., COKER, L.D., TURNBULL, T.A. & MORITA, E.T. (1989). Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. J. Clin. Invest., 84, 1220-1225.
14. MAKOVEC, F., CHRISTE, R., BANI, M., PACINI, M.A., SETNIKAR, I. & ROVATI, L.A. (1985). New glutaramic acid derivatives with potent competitive and specific cholecystokinin-antagonistic activity. Arzneim.-Forsch, Drug Res., 35, 1048-1051.
15. MEYER, B.M., BEGLINGER, C., JANSEN, J.B.M.J., ROVATI, L.C., WERTH, B.A., HILDEBRAND, O., ZACH, D. & STALDER, G.A. (1989). Role of cholecystokinin in regulation of gastrointestinal mortor functions. Lancet, ii, 12-15.
16. MILLS, J.G. & WOOD, J.R. (1989). The pharmacology of histamine H2-receptor antagonists. Methods Find Exp Clin. Pharmacol., 11, 87-95.
17. MORAN, T.H., ROBINSON, P.H., GOLDRICH, M.S. & MCHUGH, P.R. (1986). Two brain cholecystokinin receptors: Implications for behavioural actions. Brain Res., 362, 175-179.
18. NIEDERAU, C., FABER, S. & KARAUS, M. (1992). Cholecystokinin's role in regulation of colonic motility in health and irritable bowel syndrome. Gastroenterology, 102, 1889-1898.
19. NIEDERAU, M., NIEDERAU, C., STROHMEYER, G. & GRENDELL, J.H. (1989). Comparative effects of CCK receptor antagonists on rat pancreatic secretion in vivo. Am. J. Physiol., 256, G150-G157.
20. OTSUKI, M., FUJII, M., NAKAMURA, T., OKABAYASHI, Y., TANI, S., FUJISAWA, T., KOIDE, M. & BABA, S. (1989). Loxiglumide: a new proglumide analogue with potent cholecystokinin antagonistic activity in the rat pancreas. Dig. Dis. Sci., 34, 857-864.
21. OTSUKI, M., GOLDFINE, I.D. & WILLIAMS, J.A. (1984). Diabetes in the rat is associated with a reversible postreceptor defect in cholecystokinin action. Gastroenterology, 87, 882-886.
22. OTSUKI, M., OKABAYASHI, Y., NAKAMURA, T., FUJII, M., TANI, S., FUJISAWA, T. & BABA, S. (1988). Effects of new nonpeptide cholecystokinin antagonists L-364,718 and CR1392 on cholecystokinin stimulation of exocrine rat pancreas. Biomed. Res., 9, 429-436.
23. OTSUKI, M. & WILLIAMS, J.A. (1982). Effect of diabetes mellitus on the regulation of enzyme secretion by isolated rat pancreatic acini. J. Clin. Invest., 70, 148-156.
24. ROVATI, L.C. (1991). Perspectives of CCK antagonists in pancreatic research and clinical use. Int. J. Pancreatol., 8, 215-226.
25. SAITO, A., SANKARAN, H., GOLDFINE, I.D. & WILLIAMS, J.A. (1980). Cholecystokinin receptors in the brain: Characterization and distribution. Science, 208, 1155-1156.
26. SCHMIDT, W.E., CREUTZFELDT, W., SCHLESER, A., CHOUDHURY, A.R., NUSTEDE, R., HOCKER, M., NITSCHE, R., SOSTMANN, H., ROVATI, L.C. & FOLSCH, U.R. (1991). Role of CCK in regulation of pancreaticobiliary functions and GI motility in humans: effects of loxiglumide. Am. J. Physiol., 260, G197-G206.
27. SETNIKAR, I., BANI, M., CEREDA, R., CHISTE, R., MAKOVEC, F., PACINI, M.A., REVEL, L., ROVATI, L.C. & ROVATI, L.A. (1987). Pharmacological characterization of a new potent and specific nonpolypeptidic cholecystokinin antagonist. Arzneim.-Forsch. Drug Res., 37, 703-707.
28. TANI, S., ITOH, H., KOIDE, M., OKABAYASHI, Y. & OTSUKI, M. (1993). Involvement of endogenous cholecystokinin in the development of acute pancreatitis induced by closed duodenal loop. Pancreas, 8, 109-115.
29. WILLIAMS, J.A. (1982). Cholecystokinin: A hormone and a neurotransmitter. Biomed. Res., 3, 107-121.
30. WILLIAMS, J.A. & HOOTMAN, S.R. (1986). Stimulus-secretion coupling in pancreatic acinar cells. In The Exocrine Pancreas. ed. Go, V.L.W., Gardner, J.D., Brooks, F.P., Lebenthal, E., DiMagno, E.P. & Scheele, G.A. pp. 123-139. New York: Raven Press.
31. WOODRUFF, G.M. & HUGHES, J. (1991). Cholecystokinin antagonists. Annu. Rev. Pharmacol. Toxicol., 31, 469-501.
32. WROBLEWSKI, F. & LADUE, J.S. (1955). Lactic dehydrogenase activity in blood. Proc. Soc. Exp. Biol. Med., 90, 210-213.